Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Regeneron Pharmaceuticals Inc (REGN) vs Invesco Solar ETF (TAN) Price & Performance

Regeneron Pharmaceuticals IncTrade
Invesco Solar ETFTrade

Price performance (Past 24H)

Key statistics

Regeneron Pharmaceuticals Inc vs Invesco Solar ETF — how do they compare? Regeneron Pharmaceuticals Inc trades at $807.6 (market cap $83.43B), while Invesco Solar ETF trades at $47.82. The key difference: Regeneron Pharmaceuticals Inc pays a 0.46% dividend while Invesco Solar ETF pays none, and Regeneron Pharmaceuticals Inc is trading nearer its 52-week high, Invesco Solar ETF nearer its low. Which is the better fit depends on your goals.

REGNTAN
Market Cap
$83.43B
Sector
HealthSector/Thematic
52-Week High
$852.03$73.95
52-Week Low
$555.51$41.78
Enterprise Value
$78.14B
Dividend Yield
0.46%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Regeneron Pharmaceuticals Inc

Regeneron Pharmaceuticals (REGN) trades at $810.31, down 2.1% today, with strong fundamentals including 84.9% gross margins and consistent earnings beats. The stock shows bullish technical signals with support at $805 and resistance at $838, while analyst consensus remains strongly positive with 69% buy ratings. Recent news highlights multiple class action lawsuits related to clinical trial disclosures, creating near-term sentiment headwinds despite solid financial performance.

Outlook remains cautiously optimistic given strong profitability and analyst support, though legal risks and clinical trial uncertainties present challenges. The stock trades above consensus price target of $756.82, suggesting limited near-term upside potential despite robust fundamentals and institutional confidence.

Invesco Solar ETF

TAN trades at $49.13, up 2.27% today, but technical indicators signal a bearish trend with moving averages showing sell pressure. The solar ETF faces mixed sentiment; recent news highlights policy tailwinds from U.S. tariffs but also sector risks like market saturation and high volatility. Financial ratios are unavailable, limiting fundamental clarity, while institutional activity includes Bank of America increasing its stake in Q1 2026.

Outlook is cautious: geopolitical shifts and AI-driven energy demand offer growth potential, but headwinds include price deflation, regulatory uncertainty, and underperformance versus broad markets. Risks center on expense ratios, drawdowns, and competition, requiring careful evaluation for volatility-tolerant investors.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Regeneron Pharmaceuticals Inc

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases

Read more on REGN

About Invesco Solar ETF

TAN is a thematic ETF that tracks the MAC Global Solar Energy Index. It provides targeted exposure to the global solar industry, including manufacturers of solar panels, installers, and component suppliers like Enphase and First Solar.

Read more on TAN